Literature DB >> 8484983

Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours.

J Bartkova1, J Bartek, B Vojtesek, J Lukas, A Rejthar, J Kovarik, R R Millis, D P Lane, D M Barnes.   

Abstract

There is much interest in the range of genetic aberrations which occur in human malignancies. An immunohistochemical study has been carried out to investigate the consistency of expression of abnormally accumulated p53 protein in paired samples of archival primary and metastatic carcinomas. The staining of methacarn-fixed tissue from 136 matched pairs of mammary carcinoma and 20 cancers from other sites was completed using antibody CM-1 and DO1 in a sensitive peroxidase-conjugated streptavidin-biotin technique. The majority of tumour cells were positive in 25% and the tumours were negative in 17% of the primary carcinomas; staining was heterogeneous in the remaining cases. Staining was identical in 180/186 (96%) metastatic lesions. An ELISA assay carried out on 12 matched pairs of the tumour specimens demonstrated that altered conformation of the aberrant p53 protein present in a primary lesion was maintained in its metastasis. These data indicate that alterations in the p53 gene result in a relatively stable phenotype and that progression of disease is not usually accompanied by either further mutation or loss of the mutant allele.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484983     DOI: 10.1016/s0959-8049(05)80431-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

2.  Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: a critical comment.

Authors:  A Nickels; H Selter; M Pfreundschuh; M Montenarh; B Koch
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

3.  The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.

Authors:  Wolfgang J Köstler; Thomas Brodowicz; Gernot Hudelist; Margaretha Rudas; Reinhard Horvat; Günther G Steger; Christian F Singer; Johannes Attems; Werner Rabitsch; Negar Fakhrai; Katarzyna Elandt; Christoph Wiltschke; Michael Hejna; Christoph C Zielinski
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-29       Impact factor: 4.553

4.  Cancer cell stemness, responses to experimental genotoxic treatments, cytomegalovirus protein expression and DNA replication stress in pediatric medulloblastomas.

Authors:  Jiri Bartek; Joanna M Merchut-Maya; Apolinar Maya-Mendoza; Olesja Fornara; Afsar Rahbar; Christian Beltoft Bröchner; Astrid Sehested; Cecilia Söderberg-Nauclér; Jiri Bartek; Jirina Bartkova
Journal:  Cell Cycle       Date:  2020-02-13       Impact factor: 4.534

Review 5.  P53, apoptosis, and breast cancer.

Authors:  D M Barnes; R S Camplejohn
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

6.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

7.  The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology.

Authors:  B Newman; P G Moorman; R Millikan; B F Qaqish; J Geradts; T E Aldrich; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

8.  Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Authors:  Sonia Lain; Jonathan J Hollick; Johanna Campbell; Oliver D Staples; Maureen Higgins; Mustapha Aoubala; Anna McCarthy; Virginia Appleyard; Karen E Murray; Lee Baker; Alastair Thompson; Joanne Mathers; Stephen J Holland; Michael J R Stark; Georgia Pass; Julie Woods; David P Lane; Nicholas J Westwood
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

9.  Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen.

Authors:  Oliver D Staples; Jonathan J Hollick; Johanna Campbell; Maureen Higgins; Anna R McCarthy; Virginia Appleyard; Karen E Murray; Lee Baker; Alastair Thompson; Sebastien Ronseaux; Alexandra M Z Slawin; David P Lane; Nicholas J Westwood; Sonia Lain
Journal:  Cell Cycle       Date:  2008-11-15       Impact factor: 4.534

10.  p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group.

Authors:  M Stenmark-Askmalm; O Stål; K Olsen; B Nordenskjöld
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.